IMNM Latest Press Releases

-- November 6, 2026 --

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire 4:00 PM

-- November 4, 2026 --

Immunome to Present Initial First-in-Human Clinical Data for IM-1021 in Advanced B-Cell Lymphomas at ASH 2026 Business Wire 9:01 AM

-- November 2, 2026 --

Immunome to Present at Guggenheim 3rd Annual Healthcare Innovation Conference Business Wire 7:30 AM

-- October 30, 2026 --

Immunome Announces EMA Validation of Marketing Authorization Application for Varegacestat for the Treatment of Adults with Desmoid Tumors Business Wire 7:30 AM

-- October 26, 2026 --

Immunome Presents Additional Clinical Data for Varegacestat in Desmoid Tumors at ESMO 2026 Business Wire 7:00 AM

-- October 6, 2026 --

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire 4:02 PM

-- September 30, 2026 --

Immunome Announces IND Clearance for IM-1340, a Potential First-in-Class Antibody-Drug Conjugate for the Treatment of Solid Tumors Business Wire 7:45 AM

-- September 8, 2026 --

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire 4:02 PM

-- September 2, 2026 --

Immunome to Present at the H.C. Wainwright 28th Annual Global Investment Conference Business Wire 7:45 AM

-- August 11, 2026 --

Immunome Reports Second Quarter 2026 Financial Results and Provides Business Update Business Wire 4:02 PM

-- August 6, 2026 --

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire 4:02 PM

-- July 20, 2026 --

Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-3050, an FAP-Targeted Radioligand Therapy, in Patients with FAP-Expressing Advanced Solid Tumors Business Wire 7:30 AM

-- July 8, 2026 --

Immunome Announces U.S. FDA Acceptance of New Drug Application for Varegacestat for the Treatment of Adults with Desmoid Tumors Business Wire 7:30 AM

-- July 7, 2026 --

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire 4:02 PM

-- June 11, 2026 --

Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-1617, a Potential First-in-Class ADC, in Patients with Advanced Solid Tumors Business Wire 7:30 AM

Market Data Delayed 15 Minutes